Logo
  • Careers
  • Contact Us
  • Donate
  • Subscribe
Search
  • Home
  • About
    • About
    • Board of Directors
    • Senior Leadership
    • Financial Statements
    • Global Funding & Support
  • Our Work
    • Our Work
    • Discovery
      • HIV Vaccine Translational Research Laboratory
      • Human Immunology Laboratory
      • IAVI Neutralizing Antibody Center
      • Vaccine Design and Development Laboratory
    • Translation & Product Development
    • Clinical & Epidemiology Research
      • ADVANCE
      • Clinical Research Centers
      • Clinical Research Standards
      • HIV Epidemiology
    • Global Community Engagement
      • Africa Program
      • CASPR
      • End-User Research
      • World Bank/Japan-supported
        Partnerships | 日本政府・世銀が支援するパートナーシップ
    • IAVI DataSpace
  • Our Science
    • Our Science
    • Pipeline
    • HIV Vaccines
    • bnAbs for HIV Prevention
    • Tuberculosis Vaccines
    • Emerging Infectious Diseases Vaccines and Therapeutics
    • Snakebite
  • News & Resources
    • Latest NewsLatest News
    • Scientific Publications Scientific Publications
    • Press Releases
    • Features
    • IAVI Report
    • IAVI in the News
    • Fact Sheets & Publications
    • VOICES Newsletter
    • Media Contacts
    • Subscribe
  • Careers
  • Contact Us
  • Donate
  • Subscribe

Search

  • Home
  • About
    • About
    • Board of Directors
    • Senior Leadership
    • Financial Statements
    • Global Funding & Support
  • Our Work
    • Our Work
    • Discovery
    • Translation & Product Development
    • Clinical & Epidemiology Research
    • Global Community Engagement
    • IAVI DataSpace
  • Our Science
    • Our Science
    • Pipeline
    • HIV Vaccines
    • bnAbs for HIV Prevention
    • Tuberculosis Vaccines
    • Emerging Infectious Diseases Vaccines and Therapeutics
    • Snakebite
  • News & Resources
    • Latest NewsLatest News
    • Scientific Publications Scientific Publications
    • Press Releases
    • Features
    • IAVI Report
    • IAVI in the News
    • Fact Sheets & Publications
    • VOICES Newsletter
    • Media Contacts
    • Subscribe
COVID-19
  • Latest NewsLatest News
  • Scientific Publications Scientific Publications
  • Press Releases
  • Features
  • IAVI Report
  • IAVI in the News
  • Fact Sheets & Publications
  • VOICES Newsletter
  • Media Contacts
  • Subscribe

Scientific Publications

Filter By:

 

 
Filters

Dijkstra M, de Bree GJ, Stolte IG, Davidovich U, Sanders EJ, Prins M, Schim van der Loeff MFDevelopment and validation of a risk score to assist screening for acute HIV-1 infection among men who have sex with men. BMC Infect. Dis. 2017;17(1):425 doi: 10.1186/s12879-017-2508-4

Abstract & Topics (Click to display abstract, topics and IAVI Projects)     FREE PMC ARTICLE

Early treatment of acute HIV-1 infection (AHI) is beneficial for patients and could reduce onward transmission. However, guidelines on whom to test for AHI with HIV-1 RNA testing are lacking.

Joseph S, Quinn K, Greenwood A, Cope AV, McKay PF, Hayes PJ, Kopycinski JT, Gilmour J, Miller AN, Geldmacher C, Nadai Y, Ahmed MI, Montefiori DC, Dally L, Bouliotis G, Lewis DJ, Tatoud R, Wagner R, Esteban M, Shattock RJ, McCormack S, Weber JA Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes. Front Immunol 2017;8:149 doi: 10.3389/fimmu.2017.00149

Abstract & Topics (Click to display abstract, topics and IAVI Projects)    

There remains an urgent need for a prophylactic HIV vaccine. We compared combined MVA and adjuvanted gp140 to sequential MVA/gp140 after DNA priming. We expected Env-specific CD4+ T-cells after DNA and MVA priming, and Env-binding antibodies in 100% individuals after boosting with gp140 and that combined vaccines would not compromise safety and might augment immunogenicity. Forty volunteers were primed three times with DNA plasmids encoding (CN54) env and (ZM96) gag-pol-nef at 0, 4 and 8 weeks then boosted with MVA-C (CN54 env and gag-pol-nef) and glucopyranosyl lipid adjuvant-aqueous formulation (GLA-AF) adjuvanted CN54gp140. They were randomised to receive them in combination at the same visit at 16 and 20 weeks (accelerated) or sequentially with MVA-C at 16, 20, and GLA-AF/gp140 at 24 and 28 weeks (standard). All vaccinations were intramuscular. Primary outcomes included ≥grade 3 safety events and the titer of CN54gp140-specific binding IgG. Other outcomes included neutralization, binding antibody specificity and T-cell responses. Two participants experienced asymptomatic ≥grade 3 transaminitis leading to discontinuation of vaccinations, and three had grade 3 solicited local or systemic reactions. A total of 100% made anti-CN54gp140 IgG and combining vaccines did not significantly alter the response; geometric mean titer 6424 (accelerated) and 6578 (standard); neutralization of MW965.2 Tier 1 pseudovirus was superior in the standard group (82 versus 45% responders,  = 0.04). T-cell ELISpot responses were CD4+ and Env-dominant; 85 and 82% responding in the accelerated and standard groups, respectively. Vaccine-induced IgG responses targeted multiple regions within gp120 with the V3 region most immunodominant and no differences between groups detected. Combining MVA and gp140 vaccines did not result in increased adverse events and did not significantly impact upon the titer of Env-specific binding antibodies, which were seen in 100% individuals. The approach did however affect other immune responses; neutralizing antibody responses, seen only to Tier 1 pseudoviruses, were poorer when the vaccines were combined and while T-cell responses were seen in >80% individuals in both groups and similarly CD4 and Env dominant, their breadth/polyfunctionality tended to be lower when the vaccines were combined, suggesting attenuation of immunogenicity and cautioning against this accelerated regimen.

Sok D, Pauthner M, Briney B, Lee JH, Saye-Francisco KL, Hsueh J, Ramos A, Le KM, Jones M, Jardine JG, Bastidas R, Sarkar A, Liang CH, Shivatare SS, Wu CY, Schief WR, Wong CH, Wilson IA, Ward AB, Zhu J, Poignard P, Burton DRA Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans. Immunity 2016;45(1):31-45 doi: 10.1016/j.immuni.2016.06.026

Abstract & Topics (Click to display abstract, topics and IAVI Projects)     FREE PMC ARTICLE

The dense patch of high-mannose-type glycans surrounding the N332 glycan on the HIV envelope glycoprotein (Env) is targeted by multiple broadly neutralizing antibodies (bnAbs). This region is relatively conserved, implying functional importance, the origins of which are not well understood. Here we describe the isolation of new bnAbs targeting this region. Examination of these and previously described antibodies to Env revealed that four different bnAb families targeted the (324)GDIR(327) peptide stretch at the base of the gp120 V3 loop and its nearby glycans. We found that this peptide stretch constitutes part of the CCR5 co-receptor binding site, with the high-mannose patch glycans serving to camouflage it from most antibodies. GDIR-glycan bnAbs, in contrast, bound both (324)GDIR(327) peptide residues and high-mannose patch glycans, which enabled broad reactivity against diverse HIV isolates. Thus, as for the CD4 binding site, bnAb effectiveness relies on circumventing the defenses of a critical functional region on Env.

MacLeod DT, Choi NM, Briney B, Garces F, Ver LS, Landais E, Murrell B, Wrin T, Kilembe W, Liang CH, Ramos A, Bian CB, Wickramasinghe L, Kong L, Eren K, Wu CY, Wong CH, Kosakovsky Pond SL, Wilson IA, Burton DR, Poignard PEarly Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose Patch. Immunity 2016;44(5):1215-26 doi: 10.1016/j.immuni.2016.04.016

Abstract & Topics (Click to display abstract, topics and IAVI Projects)     FREE PMC ARTICLE

The high-mannose patch on HIV Env is a preferred target for broadly neutralizing antibodies (bnAbs), but to date, no vaccination regimen has elicited bnAbs against this region. Here, we present the development of a bnAb lineage targeting the high-mannose patch in an HIV-1 subtype-C-infected donor from sub-Saharan Africa. The Abs first acquired autologous neutralization, then gradually matured to achieve breadth. One Ab neutralized >47% of HIV-1 strains with only ∼11% somatic hypermutation and no insertions or deletions. By sequencing autologous env, we determined key residues that triggered the lineage and participated in Ab-Env coevolution. Next-generation sequencing of the Ab repertoire showed an early expansive diversification of the lineage followed by independent maturation of individual limbs, several of them developing notable breadth and potency. Overall, the findings are encouraging from a vaccine standpoint and suggest immunization strategies mimicking the evolution of the entire high-mannose patch and promoting maturation of multiple diverse Ab pathways.

Gosmann C, Anahtar MN, Handley SA, Farcasanu M, Abu-Ali G, Bowman BA, Padavattan N, Desai C, Droit L, Moodley A, Dong M, Chen Y, Ismail N, Ndung'u T, Ghebremichael MS, Wesemann DR, Mitchell C, Dong KL, Huttenhower C, Walker BD, Virgin HW, Kwon DSLactobacillus-Deficient Cervicovaginal Bacterial Communities Are Associated with Increased HIV Acquisition in Young South African Women. Immunity 2017;46(1):29-37 doi: S1074-7613(16)30519-2

Abstract & Topics (Click to display abstract, topics and IAVI Projects)     FREE PMC ARTICLE

Elevated inflammation in the female genital tract is associated with increased HIV risk. Cervicovaginal bacteria modulate genital inflammation; however, their role in HIV susceptibility has not been elucidated. In a prospective cohort of young, healthy South African women, we found that individuals with diverse genital bacterial communities dominated by anaerobes other than Gardnerella were at over 4-fold higher risk of acquiring HIV and had increased numbers of activated mucosal CD4 T cells compared to those with Lactobacillus crispatus-dominant communities. We identified specific bacterial taxa linked with reduced (L. crispatus) or elevated (Prevotella, Sneathia, and other anaerobes) inflammation and HIV infection and found that high-risk bacteria increased numbers of activated genital CD4 T cells in a murine model. Our results suggest that highly prevalent genital bacteria increase HIV risk by inducing mucosal HIV target cells. These findings might be leveraged to reduce HIV acquisition in women living in sub-Saharan Africa.

Martinez-Murillo P, Tran K, Guenaga J, Lindgren G, Àdori M, Feng Y, Phad GE, Vázquez Bernat N, Bale S, Ingale J, Dubrovskaya V, O'Dell S, Pramanik L, Spångberg M, Corcoran M, Loré K, Mascola JR, Wyatt RT, Karlsson Hedestam GBParticulate Array of Well-Ordered HIV Clade C Env Trimers Elicits Neutralizing Antibodies that Display a Unique V2 Cap Approach. Immunity 2017;46(5):804-817.e7 doi: S1074-7613(17)30186-3

Abstract & Topics (Click to display abstract, topics and IAVI Projects)     FREE PMC ARTICLE

The development of soluble envelope glycoprotein (Env) mimetics displaying ordered trimeric symmetry has ushered in a new era in HIV-1 vaccination. The recently reported native, flexibly linked (NFL) design allows the generation of native-like trimers from clinical isolates at high yields and homogeneity. As the majority of infections world-wide are of the clade C subtype, we examined responses in non-human primates to well-ordered subtype C 16055 trimers administered in soluble or high-density liposomal formats. We detected superior germinal center formation and enhanced autologous neutralizing antibodies against the neutralization-resistant (tier 2) 16055 virus following inoculation of liposome-arrayed trimers. Epitope mapping of the neutralizing monoclonal antibodies (mAbs) indicated major contacts with the V2 apex, and 3D electron microscopy reconstructions of Fab-trimer complexes revealed a horizontal binding angle to the Env spike. These vaccine-elicited mAbs target the V2 cap, demonstrating a means to accomplish tier 2 virus neutralization by penetrating the dense N-glycan shield.

Guenaga J, Garces F, de Val N, Stanfield RL, Dubrovskaya V, Higgins B, Carrette B, Ward AB, Wilson IA, Wyatt RTGlycine Substitution at Helix-to-Coil Transitions Facilitates the Structural Determination of a Stabilized Subtype C HIV Envelope Glycoprotein. Immunity 2017;46(5):792-803.e3 doi: S1074-7613(17)30179-6

Abstract & Topics (Click to display abstract, topics and IAVI Projects)     FREE PMC ARTICLE

Advances in HIV-1 envelope glycoprotein (Env) design generate native-like trimers and high-resolution clade A, B, and G structures and elicit neutralizing antibodies. However, a high-resolution clade C structure is critical, as this subtype accounts for the majority of HIV infections worldwide, but well-ordered clade C Env trimers are more challenging to produce due to their instability. Based on targeted glycine substitutions in the Env fusion machinery, we defined a general approach that disfavors helical transitions leading to post-fusion conformations, thereby favoring the pre-fusion state. We generated a stabilized, soluble clade C Env (16055 NFL) and determined its crystal structure at 3.9 Å. Its overall conformation is similar to SOSIP.664 and native Env trimers but includes a covalent linker between gp120 and gp41, an engineered 201-433 disulfide bond, and density corresponding to 22 N-glycans. Env-structure-guided design strategies resulted in multiple homogeneous cross-clade immunogens with the potential to advance HIV vaccine development.

Steichen JM, Kulp DW, Tokatlian T, Escolano A, Dosenovic P, Stanfield RL, McCoy LE, Ozorowski G, Hu X, Kalyuzhniy O, Briney B, Schiffner T, Garces F, Freund NT, Gitlin AD, Menis S, Georgeson E, Kubitz M, Adachi Y, Jones M, Mutafyan AA, Yun DS, Mayer CT, Ward AB, Burton DR, Wilson IA, Irvine DJ, Nussenzweig MC, Schief WRHIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies. Immunity 2016;45(3):483-496 doi: S1074-7613(16)30340-5

Abstract & Topics (Click to display abstract, topics and IAVI Projects)     FREE PMC ARTICLE

Broadly neutralizing antibodies (bnAbs) against the N332 supersite of the HIV envelope (Env) trimer are the most common bnAbs induced during infection, making them promising leads for vaccine design. Wild-type Env glycoproteins lack detectable affinity for supersite-bnAb germline precursors and are therefore unsuitable immunogens to prime supersite-bnAb responses. We employed mammalian cell surface display to design stabilized Env trimers with affinity for germline-reverted precursors of PGT121-class supersite bnAbs. The trimers maintained native-like antigenicity and structure, activated PGT121 inferred-germline B cells ex vivo when multimerized on liposomes, and primed PGT121-like responses in PGT121 inferred-germline knockin mice. Design intermediates have levels of epitope modification between wild-type and germline-targeting trimers; their mutation gradient suggests sequential immunization to induce bnAbs, in which the germline-targeting prime is followed by progressively less-mutated design intermediates and, lastly, with native trimers. The vaccine design strategies described could be utilized to target other epitopes on HIV or other pathogens.

Kiwanuka N, Ssetaala A, Ssekandi I, Nalutaaya A, Kitandwe PK, Ssempiira J, Bagaya BS, Balyegisawa A, Kaleebu P, Hahn J, Lindan C, Sewankambo NK

Population attributable fraction of incident HIV infections associated with alcohol consumption in fishing communities around Lake Victoria, Uganda. PLoS ONE 2017;12(2):e0171200 doi: 10.1371/journal.pone.0171200

Abstract & Topics (Click to display abstract, topics and IAVI Projects)     FREE PMC ARTICLE

Although the association between alcohol consumption and HIV risk is well documented, few studies have examined the magnitude of new HIV infections that could be prevented by controlling alcohol use. We report the population attributable fraction (PAF) of incident HIV infections due to alcohol consumption among the HIV high-risk population of fishing communities along Lake Victoria, Uganda.

Topics: HIV Epidemiology

Keywords: Fishing Communities

Das S, Boliar S, Samal S, Ahmed S, Shrivastava T, Shukla BN, Goswami S, Bansal M, Chakrabarti BKIdentification and characterization of a naturally occurring, efficiently cleaved, membrane-bound, clade A HIV-1 Env, suitable for immunogen design, with properties comparable to membrane-bound BG505. Virology 2017;510:22-28 doi: S0042-6822(17)30212-X

Abstract & Topics (Click to display abstract, topics and IAVI Projects)    

Efficient cleavage of HIV-1 Env gp160 into its constituent subunits correlates with selective binding to neutralizing antibodies and are the closest mimetic of native, functional Envs. This was first demonstrated with the clade B Env, JRFL. The correlation between efficient cleavage and selective binding to neutralizing antibodies is the guiding principle for immunogen design for HIV vaccine. We have recently reported that Envs 4-2.J41 (clade C) and JRCSF (clade B) are also efficiently cleaved and show similar properties. However, an efficiently cleaved, membrane-bound clade A Env suitable for genetic vaccination has not been directly demonstrated. Here we report that BG505 and a new clade A Env, QB726.70M.ENV.C4 (or A5) are efficiently cleaved on cell membrane. A5 shows desirable antigenic properties comparable with BG505 on cell surface. A5SOSIP in supernatant displays majority of bNAb binding epitopes. Thus, both BG505 and A5 Envs can be used in DNA prime-protein boost vaccination studies.

Page 14 of 87

StartPrev...1011121314...161718NextEnd

About

About

Board of Directors

Senior Leadership

Financial Statements

Global Funding & Support

Our Work

Our Work

Discovery

Translation & Product Development

Clinical & Epidemiology Research

Global Community Engagement

IAVI DataSpace

Our Science

Our Science

Pipeline

HIV Vaccines

bnAbs for HIV Prevention

Tuberculosis Vaccines

Emerging Infectious Diseases Vaccines and Therapeutics

Snakebite

News & Resources

Latest NewsLatest News

Scientific Publications Scientific Publications

Press Releases

Features

IAVI Report

IAVI in the News

Fact Sheets & Publications

VOICES Newsletter

Media Contacts

Subscribe

icon charity navigator icon guide star icon iavi

Accessibility

Compliance

Contact IAVI

Privacy Policy

Site Map

Supplier Diversity

Terms of Use

©2021 International AIDS Vaccine Initiative. International AIDS Vaccine Initiative®, IAVI®, and the IAVI logo® are registered trademarks of the International AIDS Vaccine Initiative, Inc.